MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)

Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (?)
Ratings Breakdown: 10 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $49.30 (24.94% upside)

Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Show:
DateFirmActionRatingPrice TargetActions
9/4/2015JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/3/2015Needham & Company LLCReiterated RatingBuy$49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/1/2015Leerink SwannInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/28/2015Cowen and CompanyReiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/27/2015Piper JaffrayUpgradeNeutral -> Overweight$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2015AegisInitiated CoverageBuy$54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015JPMorgan Chase & Co.Boost Price TargetOverweight$45.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Cowen and CompanyReiterated RatingOutperform$43.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Needham & Company LLCBoost Price TargetBuy$38.00 -> $49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Piper JaffrayDowngradeOverweight -> Neutral$39.00 -> $48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015HC WainwrightReiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015Needham & Company LLCSet Price TargetBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015JPMorgan Chase & Co.Reiterated RatingBuy$40.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2015Leerink SwannInitiated CoverageOutperform$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2015Piper JaffrayReiterated RatingOverweight$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2015Jefferies GroupLower Price TargetBuy$50.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2015Needham & Company LLCLower Price TargetBuy$40.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2015HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2015Needham & Company LLCSet Price TargetBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2015JMP SecuritiesBoost Price TargetOutperform$31.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2015Needham & Company LLCReiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2015HC WainwrightInitiated CoverageBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2015Roth CapitalReiterated RatingBuy$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2015Jefferies GroupBoost Price TargetBuy$42.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/22/2014Needham & Company LLCBoost Price TargetBuy$26.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/21/2014Cowen and CompanyInitiated CoverageOutperform$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2014Morgan JosephInitiated CoverageOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2014JPMorgan Chase & Co.Initiated CoverageOverweight$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2014Jefferies GroupBoost Price Target$26.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2013Ned Davis ResearchInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 9/4/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha